Nuwellis, Inc. (22SA.F)
| Previous close | 0.2190 |
| Open | 0.2375 |
| Bid | 0.1722 x N/A |
| Ask | 0.2620 x N/A |
| Day's range | 0.2335 - 0.2375 |
| 52-week range | 0.1180 - 2.8300 |
| Volume | |
| Avg. volume | 616 |
| Market cap | 3.562M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.6900 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireNuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. Nuwellis has a successful history of collaborating with individual member hospitals within the IDN on Aquadex utilization. This new network-wide agreement signifies a broader commitment to providing advanced ul
- GlobeNewswire
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: Revenue of $1.9 million, a 2% increase over the prior-year period.Consumables sales, representing 82% of total revenue, grew 11% year-over-year.Pediatric revenue growth of 40% year over year led by a 54% increase in consumable sales.Gross m
- GlobeNewswire
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves t
